Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population
Open Access
- 6 March 2026
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 65 (6) , 665-676
Abstract
Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer‐related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one‐third of patients develop biochemical recurrence within 10 years. Although prostate‐specific antigen (PSA) is the primary biomarker used for diagnosis and monitoring, additional molecular markers such as PTEN loss and MYC amplification have been investigated to improve prognostic stratification. Liquid biopsy has emerged as a promising tool in oncology, yet the clinical significance of circulating tumor cells (CTCs) in early‐stage PCa remains uncertain. This prospective, single‐center study included 50 patients with localized prostate cancer from the Brazilian Amazon region who underwent radical prostatectomy in 2023. Peripheral blood samples were collected preoperatively and postoperatively for CTC enumeration and molecular characterization using Cytelligen SET‐iFISH and the CellSearch system. PTEN and MYC status were evaluated to further characterize the detected CTC population. CTCs were detected in all patients prior to surgery, with a significant reduction observed after radical prostatectomy ( p < 0.001); 88% of patients had no detectable CTCs postoperatively. PTEN loss was identified in 12% of patients, all of whom presented with ISUP grade ≥ 2 disease. MYC amplification was rare, observed in only one patient with Gleason score 7 and concomitant PTEN deletion. These findings suggest that perioperative CTC detection may provide clinically relevant prognostic information in localized PCa. PTEN loss appears to represent an early molecular alteration associated with adverse pathological features. Longer follow‐up is needed to determine the predictive value of these biomarkers for recurrence and long‐term outcomes.Keywords
This publication has 52 references indexed in Scilit:
- Perioperative change of circulating tumor cells in cytoreductive radical prostatectomy for oligometastatic hormone-sensitive prostate cancer: the preliminary safety evidence from long-term oncologic outcomesInternational Urology and Nephrology, 2023
- Association between PSA values and surveillance quality after prostate cancer surgeryCancer Medicine, 2019
- Evolution of the Liquid Biopsy in Metastatic Prostate CancerUrology, 2019
- The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literatureWorld Journal of Urology, 2019
- CTC clusters in cancer progression and metastasisMedical Oncology, 2016
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Quantitative RT‐PCR analysis of PSA and prostate‐specific membrane antigen mRNA to detect circulating tumor cells improves recurrence‐free survival nomogram prediction after radical prostatectomyThe Prostate, 2012
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999